132 related articles for article (PubMed ID: 8845569)
1. Biological aspects of multiple myeloma.
Epstein J; Hoover R; Kornbluth J; Barlogie B
Baillieres Clin Haematol; 1995 Dec; 8(4):721-34. PubMed ID: 8845569
[TBL] [Abstract][Full Text] [Related]
2. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
Gadó K; Domján G; Hegyesi H; Falus A
Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
[TBL] [Abstract][Full Text] [Related]
3. Malignant plasma cell lines express a functional CD28 molecule.
Zhang XG; Olive D; Devos J; Rebouissou C; Ghiotto-Ragueneau M; Ferlin M; Klein B
Leukemia; 1998 Apr; 12(4):610-8. PubMed ID: 9557621
[TBL] [Abstract][Full Text] [Related]
4. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-10 and Gp130 cytokines in human multiple myeloma.
Klein B; Lu ZY; Gu ZJ; Costes V; Jourdan M; Rossi JF
Leuk Lymphoma; 1999 Jun; 34(1-2):63-70. PubMed ID: 10350333
[TBL] [Abstract][Full Text] [Related]
6. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression.
Shapiro VS; Mollenauer MN; Weiss A
Blood; 2001 Jul; 98(1):187-93. PubMed ID: 11418479
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.
Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Kawano MM
Leuk Lymphoma; 2003 Sep; 44(9):1477-81. PubMed ID: 14565647
[TBL] [Abstract][Full Text] [Related]
8. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2).
Van Riet I; De Greef C; Aharchi F; Woischwill C; De Waele M; Bakkus M; Lacor P; Schots R; Van Camp B
Leukemia; 1997 Feb; 11(2):284-93. PubMed ID: 9009094
[TBL] [Abstract][Full Text] [Related]
10. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells.
Cheung WC; Van Ness B
Leukemia; 2002 Jun; 16(6):1182-8. PubMed ID: 12040451
[TBL] [Abstract][Full Text] [Related]
11. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.
Westendorf JJ; Ahmann GJ; Armitage RJ; Spriggs MK; Lust JA; Greipp PR; Katzmann JA; Jelinek DF
J Immunol; 1994 Jan; 152(1):117-28. PubMed ID: 7504707
[TBL] [Abstract][Full Text] [Related]
12. [Signal transduction and biological function of IL-6 in a human myeloma cell line-XG-7].
Song L; Shen B
Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):845-8. PubMed ID: 11218881
[TBL] [Abstract][Full Text] [Related]
13. Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta.
Kruger M; Van Gool S; Peng XH; Coorevits L; Casteels-Van Daele M; Ceuppens JL
Immunology; 1996 May; 88(1):49-54. PubMed ID: 8707349
[TBL] [Abstract][Full Text] [Related]
14. The expression of T cell related costimulatory molecules in multiple myeloma.
Brown RD; Pope B; Yuen E; Gibson J; Joshua DE
Leuk Lymphoma; 1998 Oct; 31(3-4):379-84. PubMed ID: 9869202
[TBL] [Abstract][Full Text] [Related]
15. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.
Zhang XG; Gu JJ; Lu ZY; Yasukawa K; Yancopoulos GD; Turner K; Shoyab M; Taga T; Kishimoto T; Bataille R
J Exp Med; 1994 Apr; 179(4):1337-42. PubMed ID: 8145045
[TBL] [Abstract][Full Text] [Related]
16. Homing mechanisms in the biology of multiple myeloma.
Van Camp B; Van Riet I
Verh K Acad Geneeskd Belg; 1998; 60(3):163-94. PubMed ID: 9803879
[TBL] [Abstract][Full Text] [Related]
17. Myeloma phenotype: clues to disease origin and manifestation.
Epstein J
Hematol Oncol Clin North Am; 1992 Apr; 6(2):249-56. PubMed ID: 1582972
[TBL] [Abstract][Full Text] [Related]
18. Biological significance of heterogeneity in human myeloma cells.
Ishikawa H; Kawano MM
Int J Hematol; 1998 Dec; 68(4):363-70. PubMed ID: 9885436
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.
Ferlin M; Noraz N; Hertogh C; Brochier J; Taylor N; Klein B
Br J Haematol; 2000 Nov; 111(2):626-34. PubMed ID: 11122111
[TBL] [Abstract][Full Text] [Related]
20. Signalling and survival pathways in multiple myeloma.
Bommert K; Bargou RC; Stühmer T
Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
